Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A

SSSE:600671
15.05
CNY
-0.93
(-5.82%)
0.05EPS
230.41P/E
2.65BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A carries a market capitalization of 2.65B, placing it among publicly traded companies globally. Its enterprise value stands at 2.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.65B
Enterprise Value2.80B

Share Statistics

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A has 121.78M shares outstanding.

Shares Outstanding121.78M

Valuation Ratios

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A trades at a trailing price-to-earnings ratio of 230.41. The price-to-sales ratio is 13.10, and the price-to-book ratio stands at 33.97.

PE Ratio230.41
PS Ratio13.10
PB Ratio33.97
P/TBV Ratio37.06

Enterprise Valuation

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A trades at an EV/EBITDA multiple of 387.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 13.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 387.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.80B versus a market cap of 2.65B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales13.81
EV / EBITDA387.11
EV / EBIT387.11

Financial Position

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A maintains a current ratio of 0.83, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 157.97, indicating elevated leverage, while an interest coverage ratio of 1.05 demonstrates limited ability to service its debt obligations.

Current Ratio0.83
Quick Ratio0.14
Debt / Equity157.97
Debt / EBITDA21.98
Interest Coverage1.05

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A posted a return on equity (ROE) of 16.37, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.57 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.79, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.20, useful for judging operating efficiency across full business cycles. The company generates approximately 516,821.41 in revenue per employee across its workforce of 392.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.50 indicates how many times Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)16.37
Return on Assets (ROA)2.79
Return on Invested Capital (ROIC)1.57
Return on Capital Employed (ROCE)8.20
Revenue Per Employee516,821.41
Employee Count392.00
Inventory Turnover2.50

Taxes

CNY

Over the twelve months ended September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A recorded 4.95M in income tax expense. That works out to an effective tax rate of 44.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.24M, leaving 11.52M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax4.95M
Effective Tax Rate44.03

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A's stock has declined approximately 18.78% over the past 52 weeks. The 50-day moving average sits at 20.39, while the 200-day moving average is 19.91.

52-Week Price Change-18.78%
50-Day Moving Average20.39
200-Day Moving Average19.91

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A generated 202.59M in revenue and converted that into 11.52M in net income, yielding earnings per share of 0.05. EBITDA reached 7.23M, while operating income came in at 19.10M.

Revenue202.59M
Gross Profit100.85M
Operating Income19.10M
Pretax Income11.24M
Net Income11.52M
EBITDA7.23M
EBIT7.23M
Earnings Per Share (EPS)0.05

Balance Sheet

CNY

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A holds 36.39M in cash and equivalents against 158.90M in total debt, resulting in a net debt position of 108.21M. Total book value stands at 78.11M, with working capital of -44.69M providing operational flexibility.

Cash & Cash Equivalents36.39M
Total Debt158.90M
Net Debt108.21M
Equity (Book Value)78.11M
Book Value Per Share0.64
Working Capital-44.69M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-14.57M

Margins

Over the twelve months ended September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A posted a gross margin of 49.78, reflecting its pricing power and cost economics. The operating margin of 9.43 and net profit margin of 5.69 provide insight into operational efficiency.

Gross Margin49.78
Operating Margin9.43
Pretax Margin5.55
Profit Margin5.69
EBITDA Margin3.57

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A paid dividends of 0.05 per share. The dividend payout ratio of 579.63 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.17, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A shareholders.

Dividend Per Share0.05
Payout Ratio579.63
Shareholder Yield1.17

Stock Splits

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A's most recent stock split took place on February 24, 1997 with a 2:3 split ratio.

Last Split Date2/24/1997
Split Ratio2:3

Scores

As of September 30, 2026, Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A has an Altman Z-Score of 4.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.70